Type 1 Diabetes

Adults with diabetes in the United Kingdom live fewer years on average than people without diabetes and 100 days for each year an HbA1c above 7.5%, according to study data.

Reports of patients developing new-onset type 1 diabetes in the setting of COVID-19 infection have researchers questioning whether the virus is entering and subsequently destroying beta cells in pancreatic islets, according to a speaker.

Adults with diabetes are at greater risk for experiencing traumatic fall events leading to fractures compared with healthy controls; identifying modifiable risk factors, such as medication use, may improve patient outcomes, data show.

The use of noninvasive imaging of GLP-1 receptors could detect residual, nonfunctioning beta cells in people with long-term type 1 diabetes, according to data presented at the European Association for the Study of Diabetes virtual meeting.

An automated decision support tool for optimizing insulin pump settings was noninferior to intensive insulin titration provided by physicians from specialized academic diabetes centers, according to data from a randomized controlled trial.

Youths with type 1 diabetes have weaker bone and lower muscle strength than their healthy peers, according to a presenter at the American Society for Bone and Mineral Research virtual meeting.

Children and adolescents with type 1 diabetes use continuous glucose monitoring more often when they are part of the treatment decision-making process, according to a recent study. It was the top story in endocrinology last week.

Compared with healthy peers, a cohort of children and teens with type 1 diabetes accrued less bone over 12 months, particularly those with high urinary calcium excretion, making them more susceptible to fractures, according to study data.

Children and adolescents with type 1 diabetes use continuous glucose monitoring for more days and have greater confidence when their parents involve them in the decision to initiate the device, according to a study published in Diabetes Care.

The FDA approved a next-generation hybrid closed-loop insulin delivery system for children aged 2 to 6 years with type 1 diabetes, according to an agency press release.